Académique Documents
Professionnel Documents
Culture Documents
Hector F DeLuca
impart vitamin D and rickets as a major medical problem would
disappear. Second, the irradiation of fat-soluble substances extracted from tissues could be used to generate large amounts of
vitamin D for later characterization. The structure of vitamin D2
was deduced in 1931 by Askew et al (9), and the structure of
vitamin D3 was determined through synthetic means by Windaus
et al (10). Vitamin D was discovered with many other vitamins
and is classed as a vitamin even now. However, findings from the
second half of the 20th century showed that vitamin D is truly a
prohormone and not a vitamin. Vitamin D is virtually absent from
the food supply. It is not found in plant materials (eg, vegetables,
fruits, or grains) and is present in low abundance in meats and
other animal food sources, except in rare cases such as fish liver
oils and plants such as waxy-leaf nightshade (Solanum glaucophyllum).
KEY WORDS
Vitamin D metabolism, bone, calcium homeostasis, tetany, vitamin D endocrine system, autoimmune diseases
PRODUCTION AND METABOLISM OF VITAMIN D
INTRODUCTION
Am J Clin Nutr 2004;80(suppl):1689S96S. Printed in USA. 2004 American Society for Clinical Nutrition
1689S
ABSTRACT
Vitamin D3 is a prohormone produced in skin through ultraviolet
irradiation of 7-dehydrocholesterol. It is biologically inert and must
be metabolized to 25-hydroxyvitamin D3 in the liver and then to
1,25-dihydroxyvitamin D3 in the kidney before function. The hormonal form of vitamin D3, ie, 1,25-dihydroxyvitamin D3, acts
through a nuclear receptor to carry out its many functions, including
calcium absorption, phosphate absorption in the intestine, calcium
mobilization in bone, and calcium reabsorption in the kidney. It also
has several noncalcemic functions in the body. This overview provides a brief description of the physiologic, endocrinologic, and
molecular biologic characteristics of vitamin D. It also provides
information on new selective analogs of 1,25-dihydroyvitamin D3
for therapy.
Am J Clin Nutr 2004;80(suppl):1689S96S.
1690S
DELUCA
rickets type I were identified in several studies (20). Very important was the generation of 1-hydroxylase knockout mice,
which exhibit a phenotype virtually identical to the human vitamin D-dependent rickets type I phenotype. Therefore, the enzymes that activate vitamin D have been identified.
Of major metabolic importance is the mode of disposal of
vitamin D and its hormonal forms. The cytochrome P-450 enzyme now called CYP24 was isolated in pure form by Ohyama
and Okuda (23) and the complementary DNA and gene were
cloned, which yielded a 24-hydroxylase-null mutant (reviewed
in 20). No significant phenotype resulted except for a large accumulation of 1,25(OH)2D3 in the circulation, which produced
secondary effects on cartilaginous growth (20, 24). CYP24 is an
extremely active enzyme, but the gene remains silent in vitamin
D deficiency; it is induced by the hormonal form of vitamin D
itself. Therefore, pulses of the vitamin D hormone program its
own death through induction of the 24-hydroxylase. The 24hydroxylase is able to metabolize vitamin D to its excretion
product calcitroic acid (20). 25(OH)D3 can also be degraded
through this pathway. 24-Hydroxylase and its regulation are
important factors in the determination of the circulating concentrations of the hormonal form of vitamin D.
PHYSIOLOGIC FUNCTIONS OF VITAMIN D
A diagrammatic explanation of the role of the vitamin D hormone in mineralizing the skeleton and preventing hypocalcemic
tetany is presented in Figure 3 (20). Plasma calcium concentrations are maintained at a very constant level, and this level is
supersaturating with respect to bone mineral. If the plasma becomes less than saturated with respect to calcium and phosphate,
then mineralization fails, which results in rickets among children
and osteomalacia among adults (24). The vitamin D hormone
functions to increase serum calcium concentrations through 3
separate activities. First, it is the only hormone known to induce
the proteins involved in active intestinal calcium absorption.
Furthermore, it stimulates active intestinal absorption of phosphate. Second, blood calcium concentrations remain in the normal range even when an animal is placed on a no-calcium diet.
Therefore, an animal must possess the ability to mobilize calcium
in the absence of calcium coming from the environment, ie,
of vitamin D had been isolated, chemically identified, and synthesized (15, 16). This compound, 25-hydroxyvitamin D3
[25(OH)D3], is now currently monitored in serum to indicate the
vitamin D status of patients, as discussed below. However,
25(OH)D3 itself is metabolically inactive and must be modified
before function. The final active hormone derived from vitamin
D was isolated and identified in 1971, and its structure was
deduced as 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] (17) and
confirmed by synthesis (18). The pathway that vitamin D must
follow is illustrated in Figure 2 and forms the basis of the vitamin
D endocrine system. For 2 decades, there was consistent revisitation of the concept that more than one hormone was derived
from vitamin D, and 33 metabolites of vitamin D were identified (19). However, it soon became clear that all metabolites were
either less active or rapidly cleared and were thus intermediates
in the degradation of this important molecule. The most important of these metabolites are 24,25-dihydroxyvitamin D3 and
1,24(R),25-trihydroxyvitamin D3 produced by the enzyme
CYP24, which is induced by the vitamin D hormone itself (20).
Much is known about the enzymes that produce 1,25(OH)2D3
and their regulation, but a great deal remains to be learned (20).
Two enzymes are thought to function in the 25-hydroxylation
step. They are not exclusively hepatic but are largely functionally
active in the liver. The mitochondrial enzyme, which is not specific for vitamin D, has been cloned and a knockout mouse strain
has been prepared, without any apparent effect on vitamin D
metabolism, which suggests that there is an alternate 25hydroxylase (21). A microsomal hydroxylase was recently
cloned and could represent the missing enzyme (22). The
25(OH)D3 1-hydroxylase was cloned by 3 different laboratories (reviewed in ref 20), and the sites of vitamin D-dependent
FUNCTIONS OF VITAMIN D
1691S
serve as the endocrine gland for the vitamin D hormone, 1hydroxylase concentrations are markedly elevated (30, 31). This
signals the vitamin D hormone, which by itself stimulates intestinal absorption of calcium or together with parathyroid hormone, at higher concentrations, stimulates mobilization of bone
calcium and renal reabsorption of calcium. The increase in serum
calcium concentrations exceeds the set point of the calciumsensing system, shutting down the parathyroid gland-induced
cascade of events. If the plasma calcium concentrations overshoot, then the C-cells of the thyroid gland secrete the 32-amino
acid peptide calcitonin, which blocks bone calcium mobilization
(32). Calcitonin also stimulates the renal 1-hydroxylase to provide the vitamin D hormone for noncalcemic needs under normocalcemic conditions (33). The molecular mechanisms have
not been entirely determined, except for the vitamin D hormone
induction of 24-hydroxylase (CYP24).
An important aspect of the vitamin D endocrine system is that
dietary calcium is favored to support serum calcium concentrations under normal conditions but, when this fails, the system
mediates calcium mobilization from bone and reabsorption in the
kidney to satisfy the needs of the organism. This results in loss of
calcium from the skeleton and can ultimately lead to osteoporosis. Another important aspect is that, except for stimulating mineralization of the skeleton, the vitamin D hormone has not been
found to be anabolic on bone by itself.
MOLECULAR MECHANISMS OF VITAMIN D ACTIONS
1692S
DELUCA
FIGURE 6. Diagrammatic representation of the known molecular events in the regulation of gene expression by the vitamin D hormone, 1,25(OH)2D3,
acting through its receptor, VDR. The result of regulation may be either suppression or activation. RXR, retinoid X receptor; DRE, VDRE (see Figure 5); TFIIB,
transcription factor IIB; TFIID, transcription factor IID; RNAP, RNA polymerase.
FUNCTIONS OF VITAMIN D
1693S
dendritic cells that present antigens to the T cells (54). Although the mechanisms of this regulation of autoimmune diseases are not understood, the results are sufficient to warrant
investigation of vitamin D analogs for the treatment of such
diseases. As an extension of this function of vitamin D, the
utility of 1,25(OH)2D3 in helping prevent transplant rejection
has been demonstrated with both vascular and nonvascular
transplants (55).
ANALOGS OF 1,25(OH)2D3
the parathyroid gland hyperproliferates and hypersecretes parathyroid hormone, resulting in secondary hyperparathyroidism
(46). An important available treatment is the use of the vitamin D
hormone and its analogs to manage the parathyroid glands of
patients undergoing dialysis.
Another important area of investigation has been the immune system. Clearly, vitamin D deficiency affects the immune system, especially T cell-mediated immunity, whereas
vitamin D in excess actually suppresses certain aspects of the
immune system (47, 48). This has led to investigation of the
use of vitamin D compounds to suppress certain autoimmune
disorders. The first autoimmune disorder to come under scrutiny is multiple sclerosis, and experimental autoimmune encephalomyelitis has been used as an animal model. This disease can be suppressed or eliminated at any stage of
development with adequate amounts of the vitamin D hormone administered orally each day (49). However, hypercalcemia occurs with this therapy. We now know that the increase
in serum calcium concentrations plays some role in this therapeutic response. A clearer example of an autoimmune disease that is regulated by the vitamin D hormone is type 1
diabetes mellitus (50). Among nonobese diabetic rats, vitamin
D deficiency caused a marked increase in incidence and a
marked decrease in the lag time required for the initiation of
diabetes (Figure 7). Very important is the fact that large doses
of the vitamin D hormone could suppress type 1 diabetes
mellitus completely (50), preventing the destruction of islet
cells. Similar results were obtained with models of systemic
lupus (51), inflammatory bowel disease (52), and rheumatoid
arthritis (53). It is likely that the suppression of these autoimmune diseases involves the vitamin D hormone interacting
with T helper lymphocytes, which in turn suppress the inflammatory responses of T helper type 1 lymphocytes. Alternative
ideas have also been put forth, such as suppression of the
We now come to the area of the design of 1,25(OH)2D3 analogs with selective activities for use against specific diseases.
The major problem is that the primary role of 1,25(OH)2D3 is to
adjust serum calcium and phosphorus concentrations. This is its
dominant role, and the design of any analog to treat a disease
other than osteoporosis or osteomalacia must include the elimination or marked suppression of the plasma calcium-increasing
activity. Most analog development in this field has been performed with that in mind. Years of experience with modifications
of 1,25(OH)2D3 and assessments of the consequent physiologic
effects have yielded some information that is very useful for
designing analogs for particular uses. A recent development has
been the understanding that the carbon-2 position of vitamin D
not only is tolerated but actually produces a much more stable
transcription complex, compared with vitamin D analogs without carbon-2 modifications (56, 57). Our group has developed
analogs that are selective for actions on osteoblasts, particularly
the anabolic or bone-forming actions of that cell type. The most
promising of the compounds studied is 2-methylene-19-nor20S-1,25-dihydroxyvitamin D3 (2MD) (Figure 8). This compound is very selective for its action on bone, being 80 100
times more effective than the native hormone in stimulating bone
calcium mobilization while being equally effective in the intestine. Demonstrating that osteoblastic activity is favored by this
analog, incubation of 2MD with human osteoblasts caused formation of bone nodules within 2 wk (Figure 9) (58). However,
incubation of the same cells with even high concentrations of
1,25(OH)2D3 produced little or no change. These results suggest
strong bone-forming activity of 2MD. To test whether this analog
could cause bone synthesis in vivo, 2MD was given to aged
female rats that had been ovariectomized to ensure a loss of bone
mass (osteoporosis). 2MD caused a marked increase in the synthesis of new bone, yielding a high bone mass value; samples
tested for breaking strength proved to be extremely strong. In the
1694S
DELUCA
concentrations. However, much lower doses of the same compounds are able to suppress plasma parathyroid hormone concentrations, which shows that they are systemically active.
Therefore, there is great promise that new analogs with very
selective activities can be prepared. One group of analogs is very
selective in stimulating bone synthesis. Another pair of analogs
are devoid of calcium activity while retaining systemic activity
for the parathyroid glands. The latter group might be used to treat
autoimmune diseases and cancer and to suppress secondary hyperparathyroidism among patients undergoing dialysis.
ASSESMENT OF VITAMIN D STATUS
FUNCTIONS OF VITAMIN D
REFERENCES
1. Steenbock H. The induction of growth promoting and calcifying properties in a ration by exposure to light. Science 1924;60:224 5.
2. McCollum EV, Davis M. The necessity of certain lipins in the diet during
growth. J Biol Chem 1913;25:167231.
3. Mellanby E. An experimental investigation on rickets. Lancet 1919;1:
40712.
4. McCollum EV, Simmonds N, Becker JE, Shipley PG. An experimental
demonstration of the existence of a vitamin which promotes calcium
deposition. J Biol Chem 1922;53:293 8.
5. Huldshinsky K. Heilung von Rachitis durch kunstalich Hohen-sonne.
(The healing of rickets with artificial high altitude sun.) Dtsch Med
Wochenschr 1919;45:7123 (in German).
6. Chick H, Dolyell EJ, Hume EM. Studies of rickets in Vienna 1919
1922. Med Res Counc (GB) Spec Rep Ser 1923;77.
7. Steenbock H, Black A. Fat-soluble vitamins. XVII. The induction of
growth-promoting and calcifying properties in a ration by exposure to
ultraviolet light. J Biol Chem 1924;61:40522.
8. Goldblatt H, Soames KM. Studies on the fat-soluble growth-promoting
factor. Biochem J 1923;17:446 53.
9. Askew FA, Bourdillon RB, Bruce HM, Jenkins RGC, Webster TA. The
distillation of vitamin D. Proc R Soc Lond 1931;8107:76 90.
1695S
1696S
36.
37.
38.
39.
40.
41.
42.
43.
45.
46.
47.
48.
49. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model
of multiple sclerosis. Proc Natl Acad Sci USA 1996;93:7861 4.
50. Zella JB, DeLuca HF. Vitamin D and autoimmune diabetes. J Cell
Biochem 2003;88:216 22.
51. Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/1 mice. Autoimmunity 1992;12:143 8.
52. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000;130:2648 52.
53. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 prevents and ameliorates symptoms in two experimental model of human
arthritis. J Nutr 1998;128:68 72.
54. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R.
Dendritic cell modulation by 1,25-dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent
state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001;
98:6800 5.
55. Hullett DA, Cantorna MT, Redaelli C, et al. Prolongation of allograft survival by 1,25-dihydroxyvitamin D3. Transplantation 1998;66:824 8.
56. Sicinski RR, Prahl JM, Smith CM, DeLuca HF. New 1,25-dihydroxy19-norvitamin D3 compounds of high biological activity: synthesis and
biological evaluation of 2-hydroxymethyl, 2-methyl and 2-methylene
analogs. J Med Chem 1998;41:466274.
57. Yamamoto H, Shevde NK, Warrier A, Plum LA, DeLuca HF, Pike JW.
2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem 2003;278:31756 65.
58. Shevde NK, Plum LA, Clagett-Dame M, Yamamoto H, Pike JW, DeLuca HF. A novel potent analog of 1,25-dihydroxyvitamin D3 selectively
induces bone formation. Proc Natl Acad Sci USA 2002;99:1348791.
59. Plum LA, Prahl JM, Ma X, et al. Biologically active noncalcemic analogs of 1,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc Natl Acad Sci USA 2004;101:6900 4.
60. Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the
diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 2004;88:31527.
61. Shepard RM, DeLuca HF. Plasma concentrations of vitamin D3 and its
metabolites in the rat as influenced by vitamin D3 or 25-hydroxyvitamin
D3 intakes. Arch Biochem Biophys 1980;202:4353.
44.
DELUCA